Mr. Khemani brings more than 25 years of global pharmaceutical experience to Scilex, a privately held clinical development and commercial company based in Palo Alto, California. Mr. Khemani has been SVP Chief Commercial Officer of Scilex since March 2019. He manages Scilex sales, sales operations, marketing, market research, and managed care operations, including its U.S. promotional role and interactions with overseas partners, commercial development, and international operations. In addition to his 25 years of senior management experience in the industry, he successfully launched specialty and large market products including Zelmac / Zelnorm for IBS-D, readiness for Dexpramipexole (dex) in ALS and Parkinson’s Disease, Cubicin, an injectable antibiotic in EU and developed launch plans for Pulminique, an inhaled cyclosporine, for US and EU, and Abilify a $7 billion product. His therapeutic areas include pain, neurology, oncology, immunology, and CV. He worked prior to Scilex at executive-level positions at Bristol Myers Squibb, Chiron, PDL Biopharmaceuticals, Facet Biotech, and Knopp Biosciences. He holds a Bachelor’s degree in Pharmacy from Bombay University.